{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:55:55Z","timestamp":1791849355657,"version":"4.3.4"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC 2025-RC5X1000"],"award-info":[{"award-number":["RC 2025-RC5X1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"DOI":"10.1038\/s44386-026-00079-w","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:47Z","timestamp":1791826067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug repurposing in hereditary ataxia"],"prefix":"10.1038","volume":"3","author":[{"given":"Lorenzo","family":"Cipriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-1904","authenticated-orcid":false,"given":"Matteo","family":"Rossi Sebastiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Maria","family":"Santorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"79_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00439-025-02744-y","volume":"144","author":"E Bregant","year":"2025","unstructured":"Bregant, E. et al. The molecular landscape of hereditary ataxia: a single-center study. Hum. Genet. 144, 545\u2013557 (2025).","journal-title":"Hum. Genet."},{"key":"79_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/cells13040319","volume":"13","author":"F Pilotto","year":"2024","unstructured":"Pilotto, F., Del Bondio, A. & Puccio, H. Hereditary ataxias: from bench to clinic, where do we stand. Cells 13, 319 https:\/\/doi.org\/10.3390\/cells13040319 (2024).","journal-title":"Cells"},{"key":"79_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1007\/s12311-023-01600-x","volume":"23","author":"F De Mattei","year":"2024","unstructured":"De Mattei, F. et al. Epidemiology of spinocerebellar ataxias in Europe. Cerebellum 23, 1176\u20131183 (2024).","journal-title":"Cerebellum"},{"key":"79_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s12311-019-01052-2","volume":"18","author":"M Beaudin","year":"2019","unstructured":"Beaudin, M. et al. The classification of autosomal recessive cerebellar ataxias: a consensus statement from the society for research on the cerebellum and ataxias task force. Cerebellum 18, 1098\u20131125 (2019).","journal-title":"Cerebellum"},{"key":"79_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tins.2024.01.004","volume":"47","author":"L Van de Vondel","year":"2024","unstructured":"Van de Vondel, L., De Winter, J., Timmerman, V. & Baets, J. Overarching pathomechanisms in inherited peripheral neuropathies, spastic paraplegias, and cerebellar ataxias. Trends Neurosci. 47, 227\u2013238 (2024).","journal-title":"Trends Neurosci."},{"key":"79_CR6","doi-asserted-by":"publisher","first-page":"8490","DOI":"10.3390\/ijms22168490","volume":"22","author":"D Galatolo","year":"2021","unstructured":"Galatolo, D. et al. Ngs in hereditary ataxia: when rare becomes frequent. Int. J. Mol. Sci. 22, 8490 https:\/\/doi.org\/10.3390\/ijms22168490 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"79_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41573-025-01164-x","volume":"24","author":"Z Tanoli","year":"2025","unstructured":"Tanoli, Z. et al. Computational drug repurposing: approaches, evaluation of in silico resources and case studies. Nat. Rev. Drug Discov. 24, 521\u2013542 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"79_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"79_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41746-024-01402-3","volume":"8","author":"M De Domenico","year":"2025","unstructured":"De Domenico, M. et al. Challenges and opportunities for digital twins in precision medicine from a complex systems perspective. NPJ Digital Med. 8, 37 https:\/\/doi.org\/10.1038\/s41746-024-01402-3 (2025).","journal-title":"NPJ Digital Med."},{"key":"79_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"79_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40\u201351 (2014).","journal-title":"Nat. Biotechnol."},{"key":"79_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"79_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20\u201333 (2016).","journal-title":"J. Health Econ."},{"key":"79_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323, 844\u2013853 (2020).","journal-title":"JAMA"},{"key":"79_CR15","doi-asserted-by":"publisher","first-page":"1460100","DOI":"10.3389\/fddsv.2024.1460100","volume":"4","author":"L Pinzi","year":"2024","unstructured":"Pinzi, L., Bisi, N. & Rastelli, G. How drug repurposing can advance drug discovery: challenges and opportunities. Front. Drug Discov. 4, 1460100 https:\/\/doi.org\/10.3389\/fddsv.2024.1460100 (2024).","journal-title":"Front. Drug Discov."},{"key":"79_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08272-z","volume":"22","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, N., Grimshaw, A. A., Axson, S. A., Choe, S. H. & Miller, J. E. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv. Res. 22, 970 https:\/\/doi.org\/10.1186\/s12913-022-08272-z (2022).","journal-title":"BMC Health Serv. Res."},{"key":"79_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo, N. Can you teach old drugs new tricks? Nature 534, 314\u2013316 (2016).","journal-title":"Nature"},{"key":"79_CR18","doi-asserted-by":"publisher","first-page":"103618","DOI":"10.1016\/j.drudis.2023.103618","volume":"28","author":"WF Salminen","year":"2023","unstructured":"Salminen, W. F., Aloba, O., Drew, A., Marcinowicz, A. & Huang, M. US FDA 505(b)(2) NDA clinical, CMC and regulatory strategy concepts to expedite drug development. Drug Discov. Today 28, 103618 https:\/\/doi.org\/10.1016\/j.drudis.2023.103618 (2023).","journal-title":"Drug Discov. Today"},{"key":"79_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0092861512443748","volume":"46","author":"AM Vogel","year":"2012","unstructured":"Vogel, A. M. Hybrid or mixed marketing authorization application in the European Union: not a trivial decision in new development programs for established drugs. Drug Inf. J. 46, 479\u2013484 (2012).","journal-title":"Drug Inf. J."},{"key":"79_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1017\/jme.2024.171","volume":"52","author":"M Scholte","year":"2024","unstructured":"Scholte, M. et al. A Regulatory roadmap for repurposing: Comparing pathways for making repurposed drugs available in the EU, UK, and US. J. Law Med. Ethics 52, 940\u2013949 (2024).","journal-title":"J. Law Med. Ethics"},{"key":"79_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.drudis.2012.02.005","volume":"17","author":"KN Meekings","year":"2012","unstructured":"Meekings, K. N., Williams, C. S. M. & Arrowsmith, J. E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov. Today 17, 660\u2013664 (2012).","journal-title":"Drug Discov. Today"},{"key":"79_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli, D. T., Michaeli, T., Albers, S., Boch, T. & Michaeli, J. C. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur. J. Health Econ. 25, 979\u2013997 (2024).","journal-title":"Eur. J. Health Econ."},{"key":"79_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","volume":"338","author":"IMD Goldstein","year":"1998","unstructured":"Goldstein, I. M. D. et al. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. 338, 1397\u20131404 (1998).","journal-title":"N. Engl. J. Med."},{"key":"79_CR24","doi-asserted-by":"crossref","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565\u20131571 (1999).","DOI":"10.1056\/NEJM199911183412102"},{"key":"79_CR25","doi-asserted-by":"crossref","unstructured":"De Villez, R. L. Topical minoxidil in androgenetic alopecia androgenetic alopecia treated with topical minoxidil. (1987).","DOI":"10.1016\/S0190-9622(87)70085-1"},{"key":"79_CR26","doi-asserted-by":"crossref","unstructured":"Tallman, M. S. et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337, 1021\u20131028 (1997).","DOI":"10.1056\/NEJM199710093371501"},{"key":"79_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJM198707233170401","volume":"317","author":"MA Fischl","year":"1987","unstructured":"Fischl, M. A. et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185\u2013191 (1987).","journal-title":"N. Engl. J. Med."},{"key":"79_CR28","doi-asserted-by":"crossref","unstructured":"Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1496\u20131952 (2000).","DOI":"10.1056\/NEJM200006293422603"},{"key":"79_CR29","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3390\/cancers11101482","volume":"11","author":"SW Leung","year":"2019","unstructured":"Leung, S. W., Chou, C. J., Huang, T. C. & Yang, P. M. An integrated bioinformatics analysis repurposes an antihelminthic drug niclosamide for treating hmga2-overexpressing human colorectal cancer. Cancers 11, 1482 https:\/\/doi.org\/10.3390\/cancers11101482 (2019).","journal-title":"Cancers"},{"key":"79_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4197-9","volume":"18","author":"S Burock","year":"2018","unstructured":"Burock, S. et al. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. BMC Cancer 18, 297 https:\/\/doi.org\/10.1186\/s12885-018-4197-9 (2018).","journal-title":"BMC Cancer"},{"key":"79_CR31","doi-asserted-by":"publisher","first-page":"e26726","DOI":"10.7554\/eLife.26726","volume":"6","author":"DS Himmelstein","year":"2017","unstructured":"Himmelstein, D. S. et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 6, e26726 https:\/\/doi.org\/10.7554\/eLife.26726 (2017).","journal-title":"Elife"},{"key":"79_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"79_CR33","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.3390\/molecules27207063","volume":"27","author":"M Rossi Sebastiano","year":"2022","unstructured":"Rossi Sebastiano, M. et al. Personalized treatment for infantile ascending hereditary spastic paralysis based on in silico strategies. Molecules 27, 7063 https:\/\/doi.org\/10.3390\/molecules27207063 (2022).","journal-title":"Molecules"},{"key":"79_CR34","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1021\/jm050362n","volume":"49","author":"GL Warren","year":"2006","unstructured":"Warren, G. L. et al. A critical assessment of docking programs and scoring functions. J. Med. Chem. 49, 5912\u20135931 (2006).","journal-title":"J. Med. Chem."},{"key":"79_CR35","doi-asserted-by":"publisher","first-page":"104138","DOI":"10.1016\/j.drudis.2024.104138","volume":"29","author":"MR Sebastiano","year":"2024","unstructured":"Sebastiano, M. R. et al. Preclinical alternative drug discovery programs for monogenic rare diseases. Should small molecules or gene therapy be used? The case of hereditary spastic paraplegias. Drug Discov. Today 29, 104138 https:\/\/doi.org\/10.1016\/j.drudis.2024.104138 (2024).","journal-title":"Drug Discov. Today"},{"key":"79_CR36","doi-asserted-by":"crossref","unstructured":"Lynch, D. R., Perlman, S. L. & Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol. 67, 941\u2013947 (2010).","DOI":"10.1001\/archneurol.2010.168"},{"key":"79_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo, M. et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76, 509\u2013521 (2014).","journal-title":"Ann. Neurol."},{"key":"79_CR38","doi-asserted-by":"publisher","first-page":"E2135841","DOI":"10.1001\/jamanetworkopen.2021.35841","volume":"4","author":"K Feil","year":"2021","unstructured":"Feil, K. et al. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia the ALCAT randomized clinical crossover trial. JAMA Netw. Open 4, E2135841 https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35841 (2021).","journal-title":"JAMA Netw. Open"},{"key":"79_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"S Romano","year":"2015","unstructured":"Romano, S. et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985\u2013991 (2015).","journal-title":"Lancet Neurol."},{"key":"79_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","volume":"21","author":"G Coarelli","year":"2022","unstructured":"Coarelli, G. et al. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 21, 225\u2013233 (2022).","journal-title":"Lancet Neurol."},{"key":"79_CR41","doi-asserted-by":"publisher","first-page":"E438","DOI":"10.1212\/CPJ.0000000000001017","volume":"11","author":"C Muth","year":"2021","unstructured":"Muth, C. et al. Fampridine and acetazolamide in EA2 and related familial EA: a prospective randomized placebo-controlled trial. Neurol. Clin. Pract. 11, E438\u2013E446 (2021).","journal-title":"Neurol. Clin. Pract."},{"key":"79_CR42","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/mds.25803","volume":"29","author":"JAM Saute","year":"2014","unstructured":"Saute, J. A. M. et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov. Disord. 29, 568\u2013573 (2014).","journal-title":"Mov. Disord."},{"key":"79_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mds.27604","volume":"34","author":"G Alfedi","year":"2019","unstructured":"Alfedi, G. et al. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich\u2019s ataxia. Mov. Disord. 34, 323\u2013334 (2019).","journal-title":"Mov. Disord."},{"key":"79_CR44","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/children11080958","volume":"11","author":"G Paparella","year":"2024","unstructured":"Paparella, G. et al. A pilot phase 2 randomized trial to evaluate the safety and potential efficacy of etravirine in Friedreich ataxia patients. Children 11, 958 https:\/\/doi.org\/10.3390\/children11080958 (2024).","journal-title":"Children"},{"key":"79_CR45","doi-asserted-by":"publisher","first-page":"107013","DOI":"10.1016\/j.parkreldis.2024.107013","volume":"124","author":"KH Yap","year":"2024","unstructured":"Yap, K. H. et al. Randomized double-blind placebo-controlled trial of the effects of oral trehalose in spinocerebellar ataxia type 3: an interim analysis. Parkinsonism Relat. Disord. 124, 107013 https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107013 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"79_CR46","doi-asserted-by":"publisher","first-page":"e6980","DOI":"10.1002\/ccr3.6980","volume":"11","author":"S Miura","year":"2023","unstructured":"Miura, S. et al. A trial of topiramate for patients with hereditary spinocerebellar ataxia. Clin. Case Rep. 11, e6980 https:\/\/doi.org\/10.1002\/ccr3.6980 (2023).","journal-title":"Clin. Case Rep."},{"key":"79_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"79_CR48","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439\u2013D444 (2022).","journal-title":"Nucleic Acids Res."},{"key":"79_CR49","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/med.70038","volume":"46","author":"M Rossi Sebastiano","year":"2026","unstructured":"Rossi Sebastiano, M., Apprato, G., Francisco, S., Ermondi, G. & Caron, G. Smart integration of structural biology and medicinal chemistry to unlock target-driven drug discovery. Med. Res. Rev. 46, 921\u2013944 (2026).","journal-title":"Med. Res. Rev."},{"key":"79_CR50","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1038\/s41596-023-00885-w","volume":"18","author":"VK Tran-Nguyen","year":"2023","unstructured":"Tran-Nguyen, V. K., Junaid, M., Simeon, S. & Ballester, P. J. A practical guide to machine-learning scoring for structure-based virtual screening. Nat. Protoc. 18, 3460\u20133511 (2023).","journal-title":"Nat. Protoc."},{"key":"79_CR51","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582\u20136594 (2012).","journal-title":"J. Med. Chem."},{"key":"79_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","volume":"13","author":"AT McNutt","year":"2021","unstructured":"McNutt, A. T. et al. GNINA 1.0: molecular docking with deep learning. J. Cheminform. 13, 43 https:\/\/doi.org\/10.1186\/s13321-021-00522-2 (2021).","journal-title":"J. Cheminform."},{"key":"79_CR53","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1021\/acs.jcim.3c00322","volume":"63","author":"J Scantlebury","year":"2023","unstructured":"Scantlebury, J. et al. A small step toward generalizability: training a machine learning scoring function for structure-based virtual screening. J. Chem. Inf. Model. 63, 2960\u20132974 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"79_CR54","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil, B. et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 52, D1180\u2013D1192 (2024).","journal-title":"Nucleic Acids Res."},{"key":"79_CR55","doi-asserted-by":"publisher","first-page":"D1633","DOI":"10.1093\/nar\/gkae1075","volume":"53","author":"T Liu","year":"2025","unstructured":"Liu, T. et al. BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data. Nucleic Acids Res. 53, D1633\u2013D1644 (2025).","journal-title":"Nucleic Acids Res."},{"key":"79_CR56","doi-asserted-by":"publisher","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","volume":"52","author":"SD Harding","year":"2024","unstructured":"Harding, S. D. et al. The IUPHAR\/BPS guide to pharmacology in 2024. Nucleic Acids Res. 52, D1438\u2013D1449 (2024).","journal-title":"Nucleic Acids Res."},{"key":"79_CR57","doi-asserted-by":"publisher","first-page":"D1353","DOI":"10.1093\/nar\/gkac1046","volume":"51","author":"D Ochoa","year":"2023","unstructured":"Ochoa, D. et al. The next-generation open targets platform: reimagined, redesigned, rebuilt. Nucleic Acids Res. 51, D1353\u2013D1359 (2023).","journal-title":"Nucleic Acids Res."},{"key":"79_CR58","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. www.broad.mit.edu\/cmap (2006)."},{"key":"79_CR59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e17 (2017).","journal-title":"Cell"},{"key":"79_CR60","doi-asserted-by":"publisher","first-page":"115258","DOI":"10.1016\/j.biopha.2023.115258","volume":"165","author":"F Figueiredo","year":"2023","unstructured":"Figueiredo, F. et al. Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation. Biomed. Pharmacother. 165, 115258 https:\/\/doi.org\/10.1016\/j.biopha.2023.115258 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"79_CR61","doi-asserted-by":"publisher","first-page":"118621","DOI":"10.1016\/j.biopha.2025.118621","volume":"192","author":"A Distefano","year":"2025","unstructured":"Distefano, A., Pappalardo, M., Turco, R., Grasso, G. & Guccione, S. Modelling-filtered drug repurposing and first-in-protein SPR validation of histone deacetylase 4 inhibitors for ataxia-telangiectasia. Biomed. Pharmacother. 192, 118621 https:\/\/doi.org\/10.1016\/j.biopha.2025.118621 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"79_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/applbiosci5020037","volume":"5","author":"L Cipriano","year":"2026","unstructured":"Cipriano, L. Virtual brain and digital twins in neurogenetics: From multimodal patient data to genomically informed, clinically actionable models. Appl. Biosci. 5, 37 https:\/\/doi.org\/10.3390\/applbiosci5020037 (2026).","journal-title":"Appl. Biosci."},{"key":"79_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fninf.2013.00010","volume":"7","author":"P Sanzleon","year":"2013","unstructured":"Sanzleon, P. et al. The virtual brain: a simulator of primate brain network dynamics. Front. Neuroinform. 7, 10 https:\/\/doi.org\/10.3389\/fninf.2013.00010 (2013).","journal-title":"Front. Neuroinform."},{"key":"79_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fninf.2014.00036","volume":"8","author":"M Marmaduke Woodman","year":"2014","unstructured":"Marmaduke Woodman, M. et al. Integrating neuroinformatics tools in TheVirtualBrain. Front. Neuroinform. 8, 36 https:\/\/doi.org\/10.3389\/fninf.2014.00036 (2014).","journal-title":"Front. Neuroinform."},{"key":"79_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neunet.2023.03.040","volume":"163","author":"M Hashemi","year":"2023","unstructured":"Hashemi, M. et al. Amortized Bayesian inference on generative dynamical network models of epilepsy using deep neural density estimators. Neural Netw. 163, 178\u2013194 (2023).","journal-title":"Neural Netw."},{"key":"79_CR66","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/epi.17310","volume":"63","author":"J Makhalova","year":"2022","unstructured":"Makhalova, J. et al. Virtual epileptic patient brain modeling: relationships with seizure onset and surgical outcome. Epilepsia 63, 1942\u20131955 (2022).","journal-title":"Epilepsia"},{"key":"79_CR67","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0083-18.2018","volume":"5","author":"H Aerts","year":"2018","unstructured":"Aerts, H. et al. Modeling brain dynamics in brain tumor patients using the virtual brain. eNeuro 5, ENEURO.0083-18.2018 https:\/\/doi.org\/10.1523\/ENEURO.0083-18.2018 (2018).","journal-title":"eNeuro"},{"key":"79_CR68","doi-asserted-by":"publisher","first-page":"116738","DOI":"10.1016\/j.neuroimage.2020.116738","volume":"213","author":"H Aerts","year":"2020","unstructured":"Aerts, H. et al. Modeling brain dynamics after tumor resection using The Virtual Brain. Neuroimage 213, 116738 https:\/\/doi.org\/10.1016\/j.neuroimage.2020.116738 (2020).","journal-title":"Neuroimage"},{"key":"79_CR69","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1093\/cercor\/bhad041","volume":"33","author":"G Mart\u00ed-Juan","year":"2023","unstructured":"Mart\u00ed-Juan, G. et al. Using The Virtual Brain to study the relationship between structural and functional connectivity in patients with multiple sclerosis: a multicenter study. Cereb. Cortex 33, 7322\u20137334 (2023).","journal-title":"Cereb. Cortex"},{"key":"79_CR70","doi-asserted-by":"publisher","first-page":"110101","DOI":"10.1016\/j.isci.2024.110101","volume":"27","author":"P Sorrentino","year":"2024","unstructured":"Sorrentino, P. et al. The virtual multiple sclerosis patient. iScience 27, 110101 https:\/\/doi.org\/10.1016\/j.isci.2024.110101 (2024).","journal-title":"iScience"},{"key":"79_CR71","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.nicl.2023.103464","volume":"39","author":"L Cipriano","year":"2023","unstructured":"Cipriano, L. et al. Reduced clinical connectome fingerprinting in multiple sclerosis predicts fatigue severity. Neuroimage Clin. 39, 103464 https:\/\/doi.org\/10.1016\/j.nicl.2023.103464 (2023).","journal-title":"Neuroimage Clin."},{"key":"79_CR72","doi-asserted-by":"publisher","first-page":"fcae112","DOI":"10.1093\/braincomms\/fcae112","volume":"6","author":"L Cipriano","year":"2024","unstructured":"Cipriano, L. et al. Flexibility of brain dynamics is increased and predicts clinical impairment in relapsing\u2013remitting but not in secondary progressive multiple sclerosis. Brain Commun. 6, fcae112 https:\/\/doi.org\/10.1093\/braincomms\/fcae112 (2024).","journal-title":"Brain Commun."},{"key":"79_CR73","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.27376","volume":"33","author":"F Lipsmeier","year":"2018","unstructured":"Lipsmeier, F. et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson\u2019s disease clinical trial. Mov. Disord. 33, 1287\u20131297 (2018).","journal-title":"Mov. Disord."},{"key":"79_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15874-4","volume":"12","author":"F Lipsmeier","year":"2022","unstructured":"Lipsmeier, F. et al. Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson\u2019s disease. Sci. Rep. 12, 12081 https:\/\/doi.org\/10.1038\/s41598-022-15874-4 (2022).","journal-title":"Sci. Rep."},{"key":"79_CR75","doi-asserted-by":"publisher","first-page":"e70181","DOI":"10.1002\/trc2.70181","volume":"11","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer\u2019s disease. Alzheimers Dement. 11, e70181https:\/\/doi.org\/10.1002\/trc2.70181 (2025).","journal-title":"Alzheimers Dement."},{"key":"79_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00592-0","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad, H. et al. Enhancing randomized clinical trials with digital twins. NPJ Syst. Biol. Appl. 11, 110 https:\/\/doi.org\/10.1038\/s41540-025-00592-0 (2025).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"79_CR77","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ng0197-62","volume":"15","author":"O Zhuchenko","year":"1997","unstructured":"Zhuchenko, O. et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15, 62\u201369 (1997).","journal-title":"Nat. Genet."},{"key":"79_CR78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41746-025-01910-w","volume":"8","author":"BH Tudor","year":"2025","unstructured":"Tudor, B. H. et al. A scoping review of human digital twins in healthcare applications and usage patterns. NPJ Digital Med. 8, 587 https:\/\/doi.org\/10.1038\/s41746-025-01910-w (2025).","journal-title":"NPJ Digital Med."},{"key":"79_CR79","doi-asserted-by":"publisher","first-page":"175628642514065","DOI":"10.1177\/17562864251406589","volume":"19","author":"L Cipriano","year":"2026","unstructured":"Cipriano, L., Angelini, C. & Maria Santorelli, F. Hereditary spastic paraplegia: from decades of therapy to future innovations. Ther. Adv. Neurol. Disord. 19, 17562864251406589 https:\/\/doi.org\/10.1177\/17562864251406589 (2026).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"79_CR80","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/nn.4135","volume":"18","author":"ES Finn","year":"2015","unstructured":"Finn, E. S. et al. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. Nat. Neurosci. 18, 1664\u20131671 (2015).","journal-title":"Nat. Neurosci."},{"key":"79_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50546-x","volume":"14","author":"A Romano","year":"2024","unstructured":"Romano, A. et al. The effect of dopaminergic treatment on whole body kinematics explored through network theory. Sci. Rep. 14, 1913 https:\/\/doi.org\/10.1038\/s41598-023-50546-x (2024).","journal-title":"Sci. Rep."},{"key":"79_CR82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clinph.2024.04.003","volume":"163","author":"A Polverino","year":"2024","unstructured":"Polverino, A. et al. Altered spreading of fast aperiodic brain waves relates to disease duration in amyotrophic lateral sclerosis. Clin. Neurophysiol. 163, 14\u201321 (2024).","journal-title":"Clin. Neurophysiol."},{"key":"79_CR83","doi-asserted-by":"publisher","first-page":"e28927","DOI":"10.7554\/eLife.28927","volume":"7","author":"M Schirner","year":"2018","unstructured":"Schirner, M., McIntosh, A. R., Jirsa, V., Deco, G. & Ritter, P. Inferring multi-scale neural mechanisms with brain network modelling. Elife 7, e28927 https:\/\/doi.org\/10.7554\/eLife.28927 (2018).","journal-title":"Elife"},{"key":"79_CR84","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.neuroimage.2016.04.049","volume":"145","author":"VK Jirsa","year":"2017","unstructured":"Jirsa, V. K. et al. The virtual epileptic patient: individualized whole-brain models of epilepsy spread. Neuroimage 145, 377\u2013388 (2017).","journal-title":"Neuroimage"},{"key":"79_CR85","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463\u2013477 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"79_CR86","doi-asserted-by":"publisher","first-page":"RP106194","DOI":"10.7554\/eLife.106194","volume":"14","author":"A Ziaeemehr","year":"2025","unstructured":"Ziaeemehr, A. et al. Virtual Brain Inference (VBI), a flexible and integrative toolkit for efficient probabilistic inference on whole-brain models. Elife 14, RP106194 https:\/\/doi.org\/10.7554\/eLife.106194 (2025).","journal-title":"Elife"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00079-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00079-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:32:21Z","timestamp":1791847941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00079-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1038\/s44386-026-00079-w","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"44"}}